drugset / Trial / NCT00496665
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
Phase 1
Completed
25 enrolled
Dana-Farber Cancer Institute
AstraZeneca · collabBrigham and Women's Hospital · collabMassachusetts General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine the safety and tolerability of the combination of Zactima with metronomic chemotherapy. Zactima is an oral anti-angiogenesis drug, which means it fights cancer by cutting off a tumor's blood supply. Thus, the drug starves the tumor by preventing the delivery of nutrients and oxygen. Metronomic chemotherapy is low dose oral chemotherapy pills which are taken daily. Unlike traditional chemotherapy, metronomic chemotherapy is thought to fight cancer like Zactima, by cutting off the blood supply to tumors. Because the dose is very low, the side effects are generally mild and very different from those with higher dose chemotherapy given by vein.
Timeline
- Start
- 2007-07
- Primary completion
- 2008-08
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Subject | Methotrexate | Small molecule | 2.5 mg | Oral |
| Subject | Vandetanib | Small molecule | 100 mg | Oral |
| Subject | Vandetanib | Small molecule | 200 mg | Oral |
| Subject | Vandetanib | Small molecule | 300 mg | Oral |